Amgen’s IMDELLTRA® Shows Significant Survival Benefit in Phase 3 Small Cell Lung Cancer Trial

Amgen announced that its Phase 3 DeLLphi-304 trial demonstrated that IMDELLTRA® (tarlatamab-dlle) significantly improves overall survival in patients with small cell lung cancer who progressed after platinum-based chemotherapy. The immunotherapy outperformed standard chemotherapy and may become a new standard of care. IMDELLTRA targets DLL3-expressing tumor cells with T cell activation, and the trial results will be presented at an upcoming medical congress. While the treatment shows promise, it carries risks of severe side effects, including cytokine release syndrome and neurotoxicity.